CRUK, University of Manchester, Roche trial opens for people with rare and pediatric cancers

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Cancer Research UK, The University of Manchester, and Roche Products Ltd. opened a multi-drug, precision medicine trial for people with rare cancers who need more treatment options. The trial is set up to recruit both pediatric and adult patients with any rare cancer type.

To access this subscriber-only content please log in or renew your subscription.

Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

The largest clinical trial to date seeking to reduce the risk of people who have survived childhood cancer from developing heart failure found that carvedilol, a blood vessel relaxing medication, is safe for childhood cancer survivors and may improve important markers of heart injury sustained as a result of chemotherapy exposure.

Login